Leukaemia Survival Gap: Why Real-World Outcomes Lag Behind Clinical Trials

For patients diagnosed with acute promyelocytic leukaemia (APL), the first 30 days are a critical window. A comprehensive new meta-analysis, pooling data from 140 studies covering almost 55,000 people, sheds light on this high-stakes period. The review calculated an average early mortality rate of 12%, with severe internal bleeding, or haemorrhage, being the primary cause of death in 57% of those cases.

Crucially, the study uncovered a stark difference between controlled research and everyday care. In interventional studies, like randomised controlled trials, the early death rate was 8%. However, in observational studies reflecting real-world clinical practice, this figure jumped to 15%. This result suggests that the successes achieved in tightly controlled research environments are not always fully translated to general patient care.

While the analysis shows an encouraging downward trend in early mortality over time, the findings underscore the need to improve and standardise the initial management of APL patients, particularly in intensive care, to help close this survival gap.